Clinical trial
Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study.
NCT00216593 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study.
- Lead sponsor
- Janssen Pharmaceutica N.V., Belgium
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2003
- Completion date
- March 31, 2008
- Enrollment
- 415 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.